Kaye Biotech Inc. had the following equity account balances at December 31, 2016: Preferred shares, $2.60, non-cumulative, Authorized: 20,600 shares Issued and outstanding: 5,300 shares 37,100 Authorized: Unlimited Issued and outstanding: 86,500 shares 292,772 Common shares, Retained eamings 41,800 On February 1 2017, 5,300 preferred shares were ued at $8.00 each. The board of directors declared and paid the annual cash dividend on the preferred shares on June 30 2017, and a 12% mmon share d dend was declared and distributed on the same day when the market price per common share was $4.35. On October 1, 2017, 20,600 common shares were issued at $4.49 each. Profit earned during 2017 was $411,800 Required: Using the information provided, prepare the statement of changes in equity for the year ended December 31, 2017. (Amounts to be deducted should be indicated by a minus sign.) KAYE BIOTECH INC. Statement of Changes in Equity For Year Ended December 31, 2017 Preferred CommonRetained Total Balanca, January 1 Balance, December 31